REFRACTORY GRADE 3A FOLLICULAR LYMPHOMA
Clinical trials for REFRACTORY GRADE 3A FOLLICULAR LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY GRADE 3A FOLLICULAR LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY GRADE 3A FOLLICULAR LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug duo shows promise for Tough-to-Treat lymphoma
Disease control Recruiting nowThis phase 2 trial tests a combination of two targeted drugs, mosunetuzumab and polatuzumab vedotin, in 41 adults with follicular lymphoma that has come back or not responded to prior therapy. The goal is to see if the combo can shrink or eliminate cancer cells while monitoring s…
Matched conditions: REFRACTORY GRADE 3A FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 17, 2026 04:12 UTC
-
New combo trial aims to close cancer care gap for minorities
Disease control Recruiting nowThis early-stage study tests whether giving two targeted drugs together is feasible for people with certain B-cell lymphomas that have returned or stopped responding to prior therapy. The drugs, zanubrutinib and sonrotoclax, work by blocking proteins that help cancer cells surviv…
Matched conditions: REFRACTORY GRADE 3A FOLLICULAR LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 17, 2026 04:10 UTC